Quotient Pharmaceuticals Manufacturing leverages key industry experts in scientific and business sectors to provide strategic advice and promote effective management and direction of the company
Board of Directors
Mr. David C. Pollack
Quotient Pharmaceuticals Manufacturing
Co-Founder, CEO, Chairman of the Board
Mr. David Pollack is a co-founder, CEO, and Chairman of the Board of Quotient Pharmaceuticals Manufacturing. Mr. Pollack dedicated over 20 years working together with his father Dr. William Pollack, a prominent immunologist who received the prestigious Lasker Medical Research Award, in developing process methodologies and advancing the revolutionary platform Quotient is based upon. With a significant base of immunological knowledge, Mr. Pollack led the development of a precise immunoglobulin fractionation process and produced the Streptococcus Pneumoniae human antibody solution. Continuing his research, he also identified, developed, and procured specific plasma donors, designed production processes, and built Quotient's clean-room facilities and laboratories. Mr. Pollack is also a financier with extensive experience spanning a wide range of business activities, including commercializing new technology, underwriting, and capital funding. With a strong background in corporate, secured-debt and project finance, he has raised significant capital across multiple business sectors and has represented more than 100 financial institutions.
As co-inventor of many key patents, Mr. Pollack has been instrumental in expanding and securing technology through the filing of a multitude of U.S. patents and more than 200 foreign applications.
Quotient Pharmaceuticals Manufacturing
Co-Founder, CEO, Chairman of the Board
Mr. David Pollack is a co-founder, CEO, and Chairman of the Board of Quotient Pharmaceuticals Manufacturing. Mr. Pollack dedicated over 20 years working together with his father Dr. William Pollack, a prominent immunologist who received the prestigious Lasker Medical Research Award, in developing process methodologies and advancing the revolutionary platform Quotient is based upon. With a significant base of immunological knowledge, Mr. Pollack led the development of a precise immunoglobulin fractionation process and produced the Streptococcus Pneumoniae human antibody solution. Continuing his research, he also identified, developed, and procured specific plasma donors, designed production processes, and built Quotient's clean-room facilities and laboratories. Mr. Pollack is also a financier with extensive experience spanning a wide range of business activities, including commercializing new technology, underwriting, and capital funding. With a strong background in corporate, secured-debt and project finance, he has raised significant capital across multiple business sectors and has represented more than 100 financial institutions.
As co-inventor of many key patents, Mr. Pollack has been instrumental in expanding and securing technology through the filing of a multitude of U.S. patents and more than 200 foreign applications.
Dr. Randal Vecchione
Quotient Pharmaceuticals Manufacturing
Co-Founder, Dir of Clinical Affairs, Board Director
Dr. Randal Vecchione is a co-founder of Quotient Pharmaceuticals Manufacturing and serves as the Director of Clinical Affairs and voting Board Member. Dr. Vecchione is a prominent reconstructive surgeon with over 44 years experience, who also currently serves as Chief of Reconstructive Plastic Surgery at Scripps Mercy Hospital and is a key member of the surgical teams at Sharp Memorial, Mercy Rady Children's Hospital San Diego, and Scripps Memorial.
Dr. Vecchione has years of frontline experience in treating rampant bacterial infections, and has seen first-hand the acute problems, suffering, and death associated with antibiotic-resistant bacteria, and treating the immune suppressed. Dr. Vecchione worked closely with Dr. Pollack for many years and together treated patients using Intravenous Gama Globulin (IVIG) who were overrun with flesh-eating or other bacterial infections resistant to antibiotic treatments.
Quotient Pharmaceuticals Manufacturing
Co-Founder, Dir of Clinical Affairs, Board Director
Dr. Randal Vecchione is a co-founder of Quotient Pharmaceuticals Manufacturing and serves as the Director of Clinical Affairs and voting Board Member. Dr. Vecchione is a prominent reconstructive surgeon with over 44 years experience, who also currently serves as Chief of Reconstructive Plastic Surgery at Scripps Mercy Hospital and is a key member of the surgical teams at Sharp Memorial, Mercy Rady Children's Hospital San Diego, and Scripps Memorial.
Dr. Vecchione has years of frontline experience in treating rampant bacterial infections, and has seen first-hand the acute problems, suffering, and death associated with antibiotic-resistant bacteria, and treating the immune suppressed. Dr. Vecchione worked closely with Dr. Pollack for many years and together treated patients using Intravenous Gama Globulin (IVIG) who were overrun with flesh-eating or other bacterial infections resistant to antibiotic treatments.
Mr. James R. Philion
Quotient Pharmaceuticals Manufacturing
Board Director
Mr. Philion has had an impressive career in the automotive industry. Among his many accomplishments, he served as Chief Operating Officer of Thrifty Car Rental Worldwide System and Executive Vice President of Pentastar Transportation Group, Inc., a division of Chrysler Corporation overseeing Thrifty Rent-a-Car and Dollar Rent-a-Car. Mr. Philion led the team responsible for restructuring the growth of Thrifty and forming its alliance with Chrysler Corporation. Under his direction, Thrifty substantially increased market share, became a publically-traded company, and was ultimately sold to Chrysler.
Quotient Pharmaceuticals Manufacturing
Board Director
Mr. Philion has had an impressive career in the automotive industry. Among his many accomplishments, he served as Chief Operating Officer of Thrifty Car Rental Worldwide System and Executive Vice President of Pentastar Transportation Group, Inc., a division of Chrysler Corporation overseeing Thrifty Rent-a-Car and Dollar Rent-a-Car. Mr. Philion led the team responsible for restructuring the growth of Thrifty and forming its alliance with Chrysler Corporation. Under his direction, Thrifty substantially increased market share, became a publically-traded company, and was ultimately sold to Chrysler.
Dr. Paul Bloom
Quotient Pharmaceuticals Manufacturing
Director of Clinical Affairs, Board Director
Dr. Bloom is a key member of the management team at Quotient and has devoted years of study to the blood plasma industry and is experienced in the regulatory process. His background in theoretical physics and other disciplines as a technology analyst have proved invaluable to our Company. He has spent the last 6+ years working with David Pollack in developing a vast knowledge base across virtually all facets of Quotient’s business. Dr. Bloom has executed the primary market/competitive research, regulatory and clinical trial modeling and financial modeling along with other activities. He has decades of experience as an investment banker and analyst raising capital for emerging companies. Dr. Bloom has worked for some of the largest investment banks as an analyst for Goldman Sachs, Citicorp, and J.P. Morgan.
Quotient Pharmaceuticals Manufacturing
Director of Clinical Affairs, Board Director
Dr. Bloom is a key member of the management team at Quotient and has devoted years of study to the blood plasma industry and is experienced in the regulatory process. His background in theoretical physics and other disciplines as a technology analyst have proved invaluable to our Company. He has spent the last 6+ years working with David Pollack in developing a vast knowledge base across virtually all facets of Quotient’s business. Dr. Bloom has executed the primary market/competitive research, regulatory and clinical trial modeling and financial modeling along with other activities. He has decades of experience as an investment banker and analyst raising capital for emerging companies. Dr. Bloom has worked for some of the largest investment banks as an analyst for Goldman Sachs, Citicorp, and J.P. Morgan.